Table 1 Baseline characteristics by treatment
Adjuvant chemotherapy | Epirubicin | No epirubicin | None | P* |
|---|---|---|---|---|
Total patients No. (%) | 205 (27.5%) | 113 (15.2%) | 427 (57.3%) | |
Age in years (mean, SD) | 53.0 (10.5) | 55.6 (12.6) | 60.5 (12.0) | < 0.001 |
Tumor size | < 0.001 | |||
≤ T1 (≤ 20 mm) | 75 (36.6%) | 59 (52.2%) | 296 (69.3%) | |
≥ T2 | 127 (62.0%) | 50 (44.2%) | 121 (28.3%) | |
unknown | 3 (1.5%) | 4 (3.5%) | 10 (2.3%) | |
Lymph nodes | < 0.001 | |||
0 | 32 (15.6%) | 45 (39.8%) | 262 (61.4%) | |
≥ 1 | 162 (79.0%) | 57 (50.4%) | 131 (30.7%) | |
unknown | 11 (5.4%) | 11 (9.7%) | 34 (8.0%) | |
Grade | < 0.001 | |||
1 | 3 (1.5%) | 4 (3.5%) | 45 (10.5%) | |
2 | 63 (30.7%) | 31 (27.4%) | 260 (60.9%) | |
> 2 | 128 (62.4%) | 77 (68.1%) | 107 (25.1%) | |
Unknown | 11 (5.4%) | 1 (0.9%) | 15 (3.5%) |